Joseph Oliveto
Vermogen: 633 666 $ op 31-05-2026
Vermogen: 633 666 $ op 31-05-2026
Mr. Joseph G.
Oliveto is a President & Chief Executive Officer at Milestone Pharmaceuticals USA, Inc. and a President, Chief Executive Officer & Director at Milestone Pharmaceuticals, Inc. He is on the Board of Directors at Milestone Pharmaceuticals, Inc. Mr. Oliveto was previously employed as a Chief Executive Officer & Director by Galleon Pharmaceuticals, Inc., a President, Chief Executive Officer & Director by Chelsea Therapeutics International Ltd., an Executive-in-Residence by A. M.
Pappas & Associates LLC, and a Director-Global Alliance by Hoffmann-La Roche, Inc. He received his undergraduate degree from Rutgers State University of New Jersey and an MBA from Rutgers State University of New Jersey.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-04-2026 | 446.244 ( 0,36% ) | 633 666 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| MILESTONE PHARMACEUTICALS INC. | Algemeen Directeur | 07-03-2017 |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Develops cardiovascular drugs | Algemeen Directeur | 07-03-2017 |
| Bedrijven | Functie | Einde |
|---|---|---|
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for breathing-control conditions | Algemeen Directeur | 01-06-2016 |
| CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Algemeen Directeur | 23-06-2014 |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Corporate Officer/Principal | 30-06-2008 |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | 01-01-2008 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 7 |
|---|---|
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company developing and commercializing therapeutics for a variety of human diseases | Health Technology |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for breathing-control conditions | Health Technology |
Milestone Pharmaceuticals, Inc.
Milestone Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures cardiovascular medicines | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Pappas Capital LLC
Pappas Capital LLC Investment ManagersFinance Pappas Ventures invests in companies located in the across the globe and primarily in United States, Canada and Asia. The firm focuses on next-generation life science, agriculture, and technology. It participates in seed and early-stage transactions. | Finance |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Milestone Pharmaceuticals USA, Inc.
Milestone Pharmaceuticals USA, Inc. Pharmaceuticals: MajorHealth Technology Develops cardiovascular drugs | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau